GL1X · GenesisL1 explorer

MolNFT v1 · #73297 · protein

Crystal structure of human cytochrome P4503A4 bound to an inhibitor ritonavir

3NXU · Cytochrome P450 3A4: “Crystal structure of human cytochrome P4503A4 bound to an inhibitor ritonavir”. X-ray diffraction, 2 ligands (HEM, RIT), 12 pockets (best druggability 0.86). MolNFT v1 #73297 on GenesisL1: 3D structure, binding…

PDB
3NXU
Type
protein
Length
914 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Cytochrome P450 3A4
EC
1.14.13.67, 1.14.13.97, 1.14.13.32
UniProt
P08684
Ligands
HEM, RIT
Pockets
12 · best druggability 0.86

Structure

x-ray diffraction · 1 distinct chain · 54% helix, 9% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BCytochrome P450 3A4 (EC 1.14.13.67, 1.14.13.97, 1.14.13.32)protein45754% helix, 9% strandP08684

Ligands and binding sites

  • HEM · Protoporphyrin IX containing Fe · ligand · 2 copies · chains A, B
  • RIT · Ritonavir · ligand · 2 copies · chains A, B
  • DMS · Dimethyl sulfoxide · additive · 6 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

12 pockets found on a 1 Å grid, 6 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111410.860.8674HEM, RIT
211560.850.8573HEM, RIT
39640.740.7768empty
46190.730.8034empty
51320.550.8227empty

Interfaces

1 interface between chains.

  • A–B · 371 Ų buried · 3 hydrogen bonds · protein-protein

Compared structures

  • 3NXU · Crystal structure of human cytochrome P4503A4 bound to an inhibitor ritonavir · the same entry in another collection · chain A against A, TM-score 1.00
  • P08684 · AlphaFold monomer V2.0 prediction for cytochrome P450 3A4 (P08684) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.